← Back to Home

Legend Biotech

NASDAQ: LEGN ↗$22.74 USD~$7B MCAP
#Cell Therapy#Oncology#Multiple Myeloma

Legend Biotech is a global clinical-stage biopharmaceutical company pioneering the development of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and solid tumors. Its lead product, CARVYKTI® (ciltacabtagene autoleucel), is approved for relapsed/refractory multiple myeloma and is co-developed with Johnson & Johnson.

Company Info

Sector:Cell therapy (CAR-T)
Headquarters:Somerset, New Jersey, United States
Founded:2014
Website:legendbiotech.com

Upcoming Milestones & Key Dates

Q2 2026 (reported)
Earnings

CARVYKTI Q2 sales update

H2 2026
Clinical

Earlier-line multiple myeloma data readouts

Late 2026
Clinical

Solid tumor pipeline expansion

Clinical Development Pipeline

CARVYKTI® (ciltacabtagene autoleucel)

Target: BCMA-directed CAR-T
Relapsed/refractory multiple myeloma
Preclinical
Phase 1
Phase 2
Phase 3
Approved

LB2102

Target: DLL3-targeted CAR-T
Small cell lung cancer
Preclinical
Phase 1
Phase 2
Phase 3
Approved

LB1908

Target: Claudin18.2 CAR-T
Relapsed/refractory gastric / esophageal cancer
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Ying Huang

Chief Executive Officer

Steve Gavel

Chief Commercial Officer, CARVYKTI

Marc L. Harrison

Chief Medical Officer

Careers & Job Openings

Senior Director, Commercial Strategic Alliances

Bridgewater, New Jersey, United States
Apply Now →

IT Vendor Manager

Bridgewater, New Jersey, United States
Apply Now →

Executive Director, Head of External Engagement

Bridgewater, New Jersey, United States
Apply Now →